For the complete report, get in touch with us at : info@netscribes.com The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines. The government initiatives section gives analyses the efforts to reduce drug prices, changes in the customs duty structure and the various control programmes undertaken by the Government. A brief overview of the drug market value chain, drug regulations and patents is presented in the next section. It analyses the pharmaceutical value chain, and focuses on the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. A snapshot of different regulatory frameworks existing in the Indian pharma industry has been shown. The section also provides a list of important patent approvals for cardiovascular drugs. The competition section gives overview of pharmaceutical companies in the country operating in the cardiovascular pharmaceutical industry. The report highlights features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. It also incorporates the recent developments in the Cardiovascular Pharmaceutical industry.

1. Cardiovascular Pharmaceuticals Market ‐
Cardiovascular Pharmaceuticals Market India
April 2012

2. Executive Summary
 Cardiovascular pharmaceuticals market in India is valued at INR X bn in 20‐‐
Market
Market  The market is expected to grow at a CAGR of y% from 20‐‐‐‐‐
 CVD segment is the second largest contributor to domestic sales, contributing around x %
Drivers: Challenges:
 Increasing patient base  Strong competition
Drivers and
 Patent expiry of blockbuster drugs  Competition from complementary and
Challenges alternative medicines
 Increasing disposable income
 Introduction of new drugs
Introduction of new drugs
 Drug value chain
Drug regulation  Phases of clinical trial
and patents
p  Approval and licensing of drugs
 Patent approvals
 Reduction in drug prices
Government  Changes in tax structure
initiatives  Control Programmes
g
 Highly fragmented market with large number of players
Major Public Companies Major Private Companies
Competition Company 1 Company 4 Company 7 Company 10 Company 1 Company 4
Company 2 Company 5 Company 8 Company 11 Company 2
Company 3 Company 6 Company 9 Company 12 Company 3
CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 2

3. •Introduction
t oduct o
•Market Overview
g
•Drivers & Challenges
•Government Initiatives
•Market Value Chain, Regulation and
Patents
•Competition
•Strategic Recommendation
•Appendix
CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 3

4. Indian cardiovascular pharma market is expected to witness
huge growth in the coming years
Indian Market – Overview Market Size and Growth
• Cardiovascular therapeutic segment belongs to the INR bn
chronic segment (comprising of cardiovascular, anti 150
x6
diabetics and neuro pshychiatry), which together y%
x5
account for around A% of the total pharma market 100 x4
x3
x2
• Cardiovascular segment is the second largest x 1
50
contributor to domestic pharmaceuticals market
contributor to domestic pharmaceuticals market
sales, with a share of x% 0
2010 2011e 2012e 2013e 2014e 2015e
 Within the cardiovascular segment, antihypertensive drugs
account for almost m% of revenue
Top Pharmaceutical Segments – 20‐‐
 Cholesterol lowering drugs account for one third of sales
Cholesterol lowering drugs account for one third of sales
0 2 4 6 8 10 12 14 16 18
• Presently the market has a size of INR X bn and is
anti‐infectives %
Y 1
expected to grow at a CAGR of y% from 20‐‐ to 20‐‐ to CVD Y 2
reach INR Y bn gastro Y 3
CNS Y 4
• Annually, B million Indians die of cardiovascular respiratory Y 5
diabetes Y 6
diseases pain y 7
gynaecology Y 8
• According to WHO estimates, by 2020, almost a% of urology y 9
oncology Y 10
cardiac patients worldwide will be Indian
cardiac patients worldwide will be Indian
Source:
CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 4

5. Drivers & Challenges ‐ Summary
Drivers Challenges
Increasing patient base Strong competition
Patent expiry of blockbuster drugs Competition from complementary and
alternative medicines
Increasing disposable income
Introduction of new drugs
CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 5

6. Government Initiatives – Summary
Reduction in drug prices
Government
Initiatives
I iti ti
Control programs
Control programs Changes in tax structure
Changes in tax structure
CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 6

7. Public: Domestic Company – A Company (1/3)
Company Information Offices and Centres – India
X Road
Corporate Address
Bangalore
Tel No.
Tel No. +91 xx xxxxx xxxxx
+91 xx xxxxx xxxxx
Fax No. +91 xx xxxxx xxxxx
Website www.ppp.com
Year of Incorporation 19‐‐
Ticker Symbol xxxxxx
Stock Exchange NNN
Products and Services
Products and Services City A
City A
Head Office
Category Products/Services
CVD, CNS, respiratory, dermatology, Key People
Pharmaceutical orthopedics, nutritional, urology, anti‐
infectives
i f i Name Designation
Infectious diseases, metabolic diseases, Person M Founder
Molecule
inflammatory/respiratory diseases, and Person N CFO
Development
oncology
Person O Head
Person Q President
Source:
CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 7

8. Public: Domestic Company – A Company (2/3)
Financial Snapshot
i i lS h Key Ratios
K i
Revenue Profit Particulars y‐o‐y change 20‐‐ 20‐‐ 20‐‐ 20‐‐
INR mn Revenue INR mn Profitability Ratios
q r Profit / Loss
10,000 p Operating Margin
s Net Margin
n Profit Before Tax Margin
5,000
m n o p 0 Return on Equity
t Return on Capital Employed
0 ‐m Return on Working Capital
20‐‐ 20‐‐ 20‐‐ 20‐‐ Return on Assets
Financial Summary Return on Fixed Assets
Cost Ratios
• The company incurred a net loss of INR xx mn in FY 20‐‐, as Operating costs (% of Sales)
compared to net profit of INR yy mn in FY 20‐‐ Administration costs (% of
• The company reported total income of INR xx bn in FY 20‐‐, Sales)
registering an increase of yy per cent over FY 20‐‐
registering an increase of yy per cent over FY 20 Interest costs (% of Sales)
Interest costs (% of Sales)
Liquidity Ratios
• The company earned an operating margin of x per cent in FY 20‐‐ a
Current Ratio
decrease of y percentage points over FY 20‐‐
Cash Ratio
• The company reported debt to equity ratio of x in FY 20‐‐, an Leverage Ratios
increase of y per cent over FY 20‐‐ Debt to Equity Ratio
Debt to Capital Ratio
b i l i
Financial Summary
Interest Coverage Ratio
Indicators Present Value Efficiency Ratios
Market Capitalization (INR) X units Fixed Asset Turnover
Total Enterprise Value (INR) Y units Asset Turnover
Current Asset Turnover
EPS (INR)
EPS (INR) Z units
Z units
Working Capital Turnover
PE Ratio (Absolute) A Capital Employed Turnover
Source: Improved Decline
CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 8

9. Public: Domestic Company – A Company (3/3)
Key Business Segments Key Geographic Segments
m n o x y z
x
x x
x x
x x y
x y y
y
y y y y z z z z
z z z z
20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐
Key Recent Developments
Description
i i News
• Company A is an integrated research based company that produces a wide range of generic medicines
Overview
• Serves customers in over 100 countries with manufacturing facilities in several countries
Cardiovascular
Cardiovascular
• Products include include Product 1 and Product 2
Pharmaceuticals
• Is making consistent effort for continual improvement in rural areas with respect to accessibility of
Key Initiatives medicines
Source:
CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 9

10. Thank you for the attention
The Cardiovascular Pharmaceuticals Market – India report is part of Netscribes’ Healthcare
Industry Series.
For more detailed information or customized research requirements please contact:
Contact Number: +91 33 4064 6215
C N b 91 33 4064 621
E‐Mail: sales@netscribes.com
Netscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on hot industries in India and other
Netscribes (India) Pvt Ltd is dedicated to disseminating information and providing quick insights on “hot” industries in India and other
emerging markets. Track our new releases and major updates in these industries on
About Netscribes
Netscribes is a knowledge‐consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &
g g f g p y p p f
business research, business & corporate intelligence, content‐management services, and knowledge‐software services. At its core lies a true
value proposition that draws upon a vast knowledge base. Netscribes is a one‐stop shop designed to fulfil clients’ profitability and growth
objectives.
Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Netscribes (India)
Disclaimer: This report is published for general information only Although high standards have been used the preparation Netscribes (India)
Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of
Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.
CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 10